Literature DB >> 12477842

Importance of B-cell responses for immunological control of variant strains of simian immunodeficiency virus.

Welkin E Johnson1, Jeffrey D Lifson, Sabine M Lang, R Paul Johnson, Ronald C Desrosiers.   

Abstract

The properties of three variants of cloned simian immunodeficiency virus strain 239 (SIV239) were compared. One strain (M5) lacked five sites for N-linked carbohydrate attachment in variable regions 1 and 2 (V1 and V2) of the gp120 envelope protein, one strain (DeltaV1-V2) completely lacked V1 and V2 sequences, and another (316) had nine mutations in the envelope that impart high replicative capacity for tissue macrophages. All three strains were capable of significant levels of fusion independent of CD4, and all three were considerably more sensitive to antibody-mediated neutralization than the parent strain from which they were derived. Upon experimental infection of rhesus monkeys, these three variant strains replicated to viral loads at peak height around day 14 that were indistinguishable from or only slightly less than those observed in monkeys infected with the parental SIV239 strain. Viral loads at the set point 20 to 50 weeks after infection, however, were more than 400- to 10,000-fold lower with the variant strains. Depletion of B cells around the time of infection with M5 resulted in less effective immunological control and much higher viral loads at the set point in two of three monkeys. The differences between SIV239 infection, where there is not effective immunological control, and SIVM5 infection, where there is effective immunological control, cannot be easily explained by differences in the inherent replicative capacity of the viruses; rather, they are more readily explained by differences in the effectiveness of the antibody response. These results suggest that resistance of SIV239 to antibody-mediated neutralization is very important for evading effective immunological control, for allowing continuous viral replication, for maintenance of moderate-to-high viral loads at set point, and for disease progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12477842      PMCID: PMC140644          DOI: 10.1128/jvi.77.1.375-381.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study.

Authors:  M W Smith; M Dean; M Carrington; C Winkler; G A Huttley; D A Lomb; J J Goedert; T R O'Brien; L P Jacobson; R Kaslow; S Buchbinder; E Vittinghoff; D Vlahov; K Hoots; M W Hilgartner; S J O'Brien
Journal:  Science       Date:  1997-08-15       Impact factor: 47.728

2.  A role for carbohydrates in immune evasion in AIDS.

Authors:  J N Reitter; R E Means; R C Desrosiers
Journal:  Nat Med       Date:  1998-06       Impact factor: 53.440

3.  Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction.

Authors:  K Suryanarayana; T A Wiltrout; G M Vasquez; V M Hirsch; J D Lifson
Journal:  AIDS Res Hum Retroviruses       Date:  1998-01-20       Impact factor: 2.205

4.  Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection.

Authors:  F Kirchhoff; T C Greenough; D B Brettler; J L Sullivan; R C Desrosiers
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

5.  Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.

Authors:  E S Rosenberg; J M Billingsley; A M Caliendo; S L Boswell; P E Sax; S A Kalams; B D Walker
Journal:  Science       Date:  1997-11-21       Impact factor: 47.728

6.  Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC)

Authors:  C Winkler; W Modi; M W Smith; G W Nelson; X Wu; M Carrington; M Dean; T Honjo; K Tashiro; D Yabe; S Buchbinder; E Vittinghoff; J J Goedert; T R O'Brien; L P Jacobson; R Detels; S Donfield; A Willoughby; E Gomperts; D Vlahov; J Phair; S J O'Brien
Journal:  Science       Date:  1998-01-16       Impact factor: 47.728

7.  Identification of highly attenuated mutants of simian immunodeficiency virus.

Authors:  R C Desrosiers; J D Lifson; J S Gibbs; S C Czajak; A Y Howe; L O Arthur; R P Johnson
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

8.  A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation.

Authors:  L G Kostrikis; Y Huang; J P Moore; S M Wolinsky; L Zhang; Y Guo; L Deutsch; J Phair; A U Neumann; D D Ho
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

9.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

10.  Viral dynamics in human immunodeficiency virus type 1 infection.

Authors:  X Wei; S K Ghosh; M E Taylor; V A Johnson; E A Emini; P Deutsch; J D Lifson; S Bonhoeffer; M A Nowak; B H Hahn
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

View more
  32 in total

1.  Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity.

Authors:  Eloísa Yuste; Jacqueline D Reeves; Robert W Doms; Ronald C Desrosiers
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

2.  Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus.

Authors:  Amitinder Kaur; Hannah B Sanford; Deirdre Garry; Sabine Lang; Sherry A Klumpp; Daisuke Watanabe; Roderick T Bronson; Jeffrey D Lifson; Margherita Rosati; George N Pavlakis; Barbara K Felber; David M Knipe; Ronald C Desrosiers
Journal:  Virology       Date:  2006-09-07       Impact factor: 3.616

3.  Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery.

Authors:  Keith Mansfield; Sabine M Lang; Marie-Claire Gauduin; Hannah B Sanford; Jeffrey D Lifson; R Paul Johnson; Ronald C Desrosiers
Journal:  J Virol       Date:  2008-02-13       Impact factor: 5.103

4.  Infectivity and neutralization of simian immunodeficiency virus with FLAG epitope insertion in gp120 variable loops.

Authors:  Melissa E Laird; Ronald C Desrosiers
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

5.  Potent antibody-mediated neutralization and evolution of antigenic escape variants of simian immunodeficiency virus strain SIVmac239 in vivo.

Authors:  Shuji Sato; Eloisa Yuste; William A Lauer; Eun Hyuk Chang; Jennifer S Morgan; Jacqueline G Bixby; Jeffrey D Lifson; Ronald C Desrosiers; Welkin E Johnson
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

6.  Envelope variation as a primary determinant of lentiviral vaccine efficacy.

Authors:  Jodi K Craigo; Baoshan Zhang; Shannon Barnes; Tara L Tagmyer; Sheila J Cook; Charles J Issel; Ronald C Montelaro
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-10       Impact factor: 11.205

7.  Analysis of SIVmac Envelope-Specific Antibodies Selected Through Phage Display.

Authors:  Sergio Ita; Mayara R Agostinho; Katherine Sullivan; Seung Yub Han; Rana Akleh; Welkin E Johnson; Ismael Ben F Fofana
Journal:  AIDS Res Hum Retroviruses       Date:  2017-02-16       Impact factor: 2.205

8.  Cell tropism of simian immunodeficiency virus in culture is not predictive of in vivo tropism or pathogenesis.

Authors:  Juan T Borda; Xavier Alvarez; Ivanela Kondova; Pyone Aye; Meredith A Simon; Ronald C Desrosiers; Andrew A Lackner
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

9.  Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239.

Authors:  Panagiotis Vagenas; Vennansha G Williams; Michael Piatak; Julian W Bess; Jeffrey D Lifson; James L Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12-01       Impact factor: 3.731

10.  Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies.

Authors:  Eloìsa Yuste; Jacqueline Bixby; Jeffrey Lifson; Shuji Sato; Welkin Johnson; Ronald Desrosiers
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.